Hims & Hers Health stock forecast: Downside momentum likely to persist near $16.91 support

Hims & Hers Health stock forecast: Downside momentum likely to persist near $16.91 support
Hims & Hers Health slides 5.98% today

Hims & Hers Health (HIMS) stock is trading at $18.56 after a decline of 5.98% for the day, moving sharply lower and closing near session lows. The price remains below its key moving averages across all observed timeframes, reflecting continued downward momentum.

HIMS price prediction
24H -0.51%
$17.41
48H -0.8%
$17.36
7D -2.46%
$17.07
1M -39.03%
$10.67
3M -54.17%
$8.02
6M -72.8%
$4.76
12M -59.77%
$7.04
Current price: $17.5 -1.0600 5.71%
Real-time Data 12:23
Daily range 17.14 Arrow from to Icon 18.70
Weekly range 18.45 Arrow from to Icon 20.87
Loading...

Highlights

  • Hims & Hers Health reported third-quarter revenue of $890.4 million, representing a 49% increase year-over-year.
  • The company posted a net loss of $33 million and lower gross margin at 57%, and it plans to broaden its weight-loss drug lineup with new products from Lilly, Foundayo, and Novo Nordisk when available.
  • Shares of Hims & Hers Health trade below key moving averages with a prevailing downtrend and high volatility, forecast range $16.91 to $20.21, and a 78% probability of further downside.

Profitability concerns grow despite strong revenue gains and product expansion

Hims & Hers Health reported third-quarter revenue of $890.4 million, marking a 49% increase year-over-year and reflecting substantial growth in business volume, according to TradingView. However, the quarter was accompanied by a net loss of $33 million and a decline in gross margin to 57%, underscoring ongoing pressures on profitability and cost structure. The company also announced an expansion to its weight-loss drug lineup, outlining plans to add new products from Lilly, Foundayo, and Novo Nordisk when available, which may support future growth opportunities though price action has remained under broader selling pressure.

Hims & Hers Health Inc. asset chart
Hims & Hers Health Inc. price dynamics. Source: TradingView.

Downside bias prevails amid oversold conditions and resistance barriers

On the technical front, HIMS/USD remains below the H1 SMA-20 at $19.51, H1 SMA-50 at $21.09, and D1 SMA-200 at $26.63, with the Ichimoku Kijun at $19.67 acting as immediate resistance to any upward moves. MACD and ADX are both confirming downside momentum, while RSI stands neutral. Stoch RSI and CCI are deep in oversold territory, which can indicate selling exhaustion, and Bull/Bear Power is negative at -0.49, suggesting sellers maintain control. The Awesome Oscillator provides no clear bias. This mix of momentum and oscillator readings highlights a prevailing downward bias with some potential for short-lived rebounds if selling subsides.

Greater downside risk seen as consolidation signals likely volatility

Looking ahead over the next several sessions, HIMS is likely to consolidate within a typical volatility band between $16.91 and $20.21. Downside is more probable, with a 78% likelihood of a move lower and just 22% for an upward reversal attempt. Should price break and close above resistance at $19.67, a short-term recovery could develop. Conversely, a decisive move below $16.91 risks accelerating bearish momentum and extending the drawdown.

Anton Kharitonov, expert at Traders Union, sees Hims & Hers Health facing clear downside pressure as the stock trades well below key resistance at the H1 SMA-20 at $19.51 and D1 SMA-200 at $26.63. Despite strong year-over-year revenue expansion, persistent net losses and declining gross margins weigh on sentiment and limit enthusiasm. Technicals reinforce the bearish picture with momentum and oscillator readings pointing to persistent seller control. "Until the $19.67 resistance is reclaimed, I remain defensive and see downside risk dominating the setup here."

Earlier, analysts noted that Hims & Hers Health shares faced persistent downside risk and bearish technical momentum. The latest technical developments and corporate updates reinforce this view, highlighting the importance of monitoring the $16.91 support as a critical level for potential downside acceleration in the near term.

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.